Publications and communications of Laura Gerardelli

Gerardelli, L., Demanche, A., Lebrun, M., Bottero, B., Bosmans, M., Havrics, E., Perin, F., Morbidelli, M., Peiffer, R., Crake, R., La Rocca, R., Marichal, T., Nokin, M.-J., & Cataldo, D. (24 April 2026). Targeting the CCL5-CCR5 Axis: A New Strategy Against Chemoresistant Mesothelioma [Poster presentation]. Predict Meso.

Havrics, E., Gerardelli, L., & Cataldo, D. (23 April 2026). Targeting macrophage-mediated immunosuppression to overcome resistance in malignant pleural mesothelioma [Poster presentation]. PREDICT-Meso International Conference, Glasgow, United Kingdom.

Gerardelli, L., Demanche, A., Lebrun, M., Bottero, B., Bosmans, M., Havrics, E., Perin, F., Morbidelli, M., Peiffer, R., Crake, R., La Rocca, R., Marichal, T., Nokin, M.-J., & Cataldo, D. (20 March 2026). Targeting the CCL5-CCR5 Axis: A New Strategy Against Chemoresistant Mesothelioma [Poster presentation]. 24th Lung Science Conference, Estoril, Portugal.

Gerardelli, L. (28 October 2025). Targeting the CCL5-CCR5 Axis: A New Strategy Against Chemoresistant Mesothelioma [Paper presentation]. Imig, Philadelphie, United States.

Hemmer, M., Crake, R., Kiweler, N., Neises, L., Dupriez, L., Gerardelli, L., Thiry, M., Peiffer, R., Peulen, O., Maquoi, E., Le Goff, C., Blomme, A., Ambrogio, C., Santamaria, D., Meiser, J., Cataldo, D., & Nokin, M.-J. (10 October 2025). Targeting metabolic adaptations in drug tolerant BRAFV600E mutant lung adenocarcinoma [Poster presentation]. Belgian Association for Cancer Research.

Hemmer, M., Crake, R., Kiweler, N., Neises, L., Dupriez, L., Thiry, M., Gerardelli, L., Peiffer, R., Peulen, O., Maquoi, E., Le Goff, C., Blomme, A., Ambrogio, C., Santamaria, D., Meiser, J., Cataldo, D., & Nokin, M.-J. (02 July 2025). Targeting metabolic adaptations in drug tolerant BRAFV600E mutant lung adenocarcinoma [Poster presentation]. ISCaM 12th annual meeting.

Gerardelli, L. (18 October 2024). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Paper presentation]. BACR.

Nokin, M.-J., Darbo, E., Richard, E., San José, S., de Hita, S., Prouzet-Mauleon, Turcs, B., Gerardelli, L., Crake, R., Velasco, V., KOOPMANSCH, B., Lambert, F., Xue, J. Y., Sang, B., Horne, J., Ziemons, E., Villanueva, A., Blomme, A., Herfs, M., ... Santamaria, D. (2024). In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. Cell Reports Medicine. doi:10.1016/j.xcrm.2024.101663

Gerardelli, L. (31 May 2024). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Paper presentation]. GSK Pulmonology Awards.

Gerardelli, L. (04 October 2023). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Poster presentation]. Tumor Heterogeneity, Plasticity and Therapy.

Gerardelli, L. (01 June 2023). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Paper presentation]. GSK Pulmonology Awards.

Gerardelli, L. (05 October 2022). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Poster presentation]. EDT Immunology, Liege, Belgium.

Gerardelli, L. (30 September 2022). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Poster presentation]. BACR, Ghent, Belgium.

Gerardelli, L. (06 September 2022). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Paper presentation]. GIGA DAY, Liege, Belgium.

Gerardelli, L. (22 June 2022). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Poster presentation]. EACR congress, Sevilla, Spain.

Gerardelli, L. (25 May 2022). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Paper presentation]. GSK Pulmonology Awards, Bruxelles, Belgium.

Gerardelli, L. (14 December 2021). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Paper presentation]. Giga Cancer Day -Uliège.

Gerardelli, L., Noël, A., & CATALDO, D. (14 December 2021). Targeting the CCL5-CCR5 axis to tackle chemoresistant malignant pleural mesothelioma [Paper presentation]. Giga Cancer Day.

Gerardelli, L., & CATALDO, D. (12 October 2021). A new understanding of the chemotherapy resistance in malignant pleural mesothelioma [Paper presentation]. Etex meeting.

Gerardelli, L., Bellefroid, M., Sepult, C., Vanwinge, C., Noël, A., & CATALDO, D. (26 May 2021). Implication of CCL5-CCR5 axis in malignant pleural mesothelioma chemoresistance [Paper presentation]. GSK Pulmonology Awards 2021.

Gerardelli, L., Bellefroid, M., Sepult, C., Vanwinge, C., Noël, A., & CATALDO, D. (08 May 2021). Implication of CCL5-CCR5 axis in Malignant Pleural Mesothelioma Chemoresistance [Poster presentation]. International Mesothelioma Interest Group (iMig).